Novavax is seeking emergency authorization of its COVID-19 booster shot in adults aged 18 and older from U.S. regulators, the company announced on Monday.
In a press release, the biotechnology company based in Maryland said it has submitted an application to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) for its protein-based booster shot.